AU2016204522A1 - Tuberous Sclerosis treatment - Google Patents

Tuberous Sclerosis treatment

Info

Publication number
AU2016204522A1
AU2016204522A1 AU2016204522A AU2016204522A AU2016204522A1 AU 2016204522 A1 AU2016204522 A1 AU 2016204522A1 AU 2016204522 A AU2016204522 A AU 2016204522A AU 2016204522 A AU2016204522 A AU 2016204522A AU 2016204522 A1 AU2016204522 A1 AU 2016204522A1
Authority
AU
Australia
Prior art keywords
tuberous sclerosis
sclerosis treatment
treatment
tuberous
documet18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016204522A
Other versions
AU2016204522B2 (en
AU2016204522C1 (en
Inventor
John Benedetto
William Berg
Ingrid Elmroth
Heidi Lane
David Lebwohl
William Sellers
Michael Stumm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to AU2016204522A priority Critical patent/AU2016204522C1/en
Publication of AU2016204522A1 publication Critical patent/AU2016204522A1/en
Publication of AU2016204522B2 publication Critical patent/AU2016204522B2/en
Priority to AU2017218980A priority patent/AU2017218980B2/en
Application granted granted Critical
Publication of AU2016204522C1 publication Critical patent/AU2016204522C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Documet18-28/06/2016 Rapamycin derivatives for use in the treatment of neurocutaneous disorders.
AU2016204522A 2006-02-02 2016-06-29 Tuberous Sclerosis treatment Active AU2016204522C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204522A AU2016204522C1 (en) 2006-02-02 2016-06-29 Tuberous Sclerosis treatment
AU2017218980A AU2017218980B2 (en) 2006-02-02 2017-08-22 Tuberous Sclerosis treatment

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0602123.2 2006-02-02
GB0603568.7 2006-02-22
GB0604593.4 2006-03-07
GB0605760.8 2006-03-22
GB0609698.6 2006-05-16
AU2011205053A AU2011205053B2 (en) 2006-02-02 2011-07-28 Tuberous Sclerosis treatment
AU2013205754A AU2013205754C1 (en) 2006-02-02 2013-05-07 Tuberous Sclerosis treatment
AU2016204522A AU2016204522C1 (en) 2006-02-02 2016-06-29 Tuberous Sclerosis treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013205754A Division AU2013205754C1 (en) 2006-02-02 2013-05-07 Tuberous Sclerosis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017218980A Division AU2017218980B2 (en) 2006-02-02 2017-08-22 Tuberous Sclerosis treatment

Publications (3)

Publication Number Publication Date
AU2016204522A1 true AU2016204522A1 (en) 2016-07-14
AU2016204522B2 AU2016204522B2 (en) 2017-06-29
AU2016204522C1 AU2016204522C1 (en) 2017-12-07

Family

ID=45420285

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2011205053A Active AU2011205053B2 (en) 2006-02-02 2011-07-28 Tuberous Sclerosis treatment
AU2012268891A Active AU2012268891B2 (en) 2006-02-02 2012-12-24 Tuberous Sclerosis treatment
AU2013205754A Active AU2013205754C1 (en) 2006-02-02 2013-05-07 Tuberous Sclerosis treatment
AU2016204522A Active AU2016204522C1 (en) 2006-02-02 2016-06-29 Tuberous Sclerosis treatment
AU2017218980A Active AU2017218980B2 (en) 2006-02-02 2017-08-22 Tuberous Sclerosis treatment

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AU2011205053A Active AU2011205053B2 (en) 2006-02-02 2011-07-28 Tuberous Sclerosis treatment
AU2012268891A Active AU2012268891B2 (en) 2006-02-02 2012-12-24 Tuberous Sclerosis treatment
AU2013205754A Active AU2013205754C1 (en) 2006-02-02 2013-05-07 Tuberous Sclerosis treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017218980A Active AU2017218980B2 (en) 2006-02-02 2017-08-22 Tuberous Sclerosis treatment

Country Status (1)

Country Link
AU (5) AU2011205053B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
AU2017218980A1 (en) 2017-09-07
AU2012268891A1 (en) 2013-01-24
AU2011205053B2 (en) 2013-02-07
AU2011205053A1 (en) 2011-08-25
AU2016204522B2 (en) 2017-06-29
AU2013205754A1 (en) 2013-05-30
AU2013205754C1 (en) 2018-01-04
AU2017218980B2 (en) 2019-03-28
AU2016204522C1 (en) 2017-12-07
AU2012268891B2 (en) 2014-07-03
AU2013205754B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
MX339116B (en) Tuberous sclerosis treatment.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
EP1893216A4 (en) Methods and compositions for the treatment of ocular disorders
EP1987141B8 (en) Compositions suitable for treating collagen-mediated diseases
IL191283A (en) Compositions for the treatment of ophthalmic disorders
AU2006224295A8 (en) N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
EP1883438A4 (en) Apparatus and techniques for reducing the effects of general anesthetics
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
PL1920781T3 (en) Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
MY147247A (en) Organic compounds and their uses
IL195906A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
HK1139861A1 (en) Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL198112A0 (en) 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
AU2006243194A8 (en) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
WO2006130493A3 (en) Heterocycles useful as modulators of ion channels
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2007015173A3 (en) Inflammation
SI1920781T1 (en) Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2017

FGA Letters patent sealed or granted (standard patent)